GeoVax Labs (NASDAQ:GOVX) PT Raised to $120.00

GeoVax Labs (NASDAQ:GOVXGet Free Report) had its price objective raised by equities researchers at HC Wainwright from $8.00 to $120.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

GeoVax Labs Stock Performance

NASDAQ GOVX traded down $0.01 on Tuesday, reaching $1.10. 621,189 shares of the stock traded hands, compared to its average volume of 81,101. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $10.24. The firm’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $2.90.

GeoVax Labs (NASDAQ:GOVXGet Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC purchased a new position in GeoVax Labs, Inc. (NASDAQ:GOVXFree Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is currently owned by institutional investors.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

See Also

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with's FREE daily email newsletter.